FY2027 Earnings Forecast for IONS Issued By HC Wainwright

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) – Investment analysts at HC Wainwright issued their FY2027 earnings estimates for Ionis Pharmaceuticals in a research note issued to investors on Wednesday, March 25th. HC Wainwright analyst M. Kapoor forecasts that the company will earn ($0.35) per share for the year. HC Wainwright has a “Buy” rating and a $120.00 price objective on the stock. The consensus estimate for Ionis Pharmaceuticals’ current full-year earnings is ($3.50) per share.

A number of other brokerages have also recently weighed in on IONS. Wall Street Zen cut Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. TD Cowen restated a “buy” rating on shares of Ionis Pharmaceuticals in a research report on Wednesday, December 3rd. Leerink Partners lifted their target price on shares of Ionis Pharmaceuticals from $102.00 to $104.00 and gave the company an “outperform” rating in a report on Tuesday, March 3rd. Bank of America upped their price target on shares of Ionis Pharmaceuticals from $86.00 to $97.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Finally, Morgan Stanley set a $95.00 price target on shares of Ionis Pharmaceuticals and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Ionis Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $90.15.

Ionis Pharmaceuticals Stock Up 2.1%

Shares of NASDAQ IONS opened at $74.24 on Thursday. The business has a 50-day moving average price of $78.99 and a 200 day moving average price of $75.56. The stock has a market cap of $12.26 billion, a PE ratio of -30.43 and a beta of 0.31. The company has a quick ratio of 3.81, a current ratio of 3.83 and a debt-to-equity ratio of 2.76. Ionis Pharmaceuticals has a 52-week low of $23.95 and a 52-week high of $86.74.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its earnings results on Wednesday, February 25th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.18). Ionis Pharmaceuticals had a negative return on equity of 68.82% and a negative net margin of 40.36%.The firm had revenue of $203.33 million for the quarter, compared to analyst estimates of $156.07 million. During the same quarter last year, the firm posted ($0.66) EPS. The firm’s revenue for the quarter was down 10.6% on a year-over-year basis.

Insiders Place Their Bets

In related news, Director Allene M. Diaz sold 54,878 shares of Ionis Pharmaceuticals stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $79.35, for a total value of $4,354,569.30. Following the transaction, the director directly owned 3,811 shares in the company, valued at $302,402.85. This trade represents a 93.51% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Shannon L. Devers sold 44,199 shares of the business’s stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $85.08, for a total transaction of $3,760,450.92. Following the completion of the transaction, the executive vice president directly owned 17,494 shares in the company, valued at $1,488,389.52. This represents a 71.64% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 1,035,882 shares of company stock valued at $80,492,247. 2.60% of the stock is owned by company insiders.

Institutional Trading of Ionis Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Capital World Investors raised its holdings in Ionis Pharmaceuticals by 41.2% during the fourth quarter. Capital World Investors now owns 17,961,299 shares of the company’s stock worth $1,420,918,000 after purchasing an additional 5,238,571 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its holdings in Ionis Pharmaceuticals by 253.3% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,800,000 shares of the company’s stock valued at $150,138,000 after purchasing an additional 2,724,400 shares in the last quarter. Geode Capital Management LLC increased its position in Ionis Pharmaceuticals by 2.7% during the 4th quarter. Geode Capital Management LLC now owns 3,148,849 shares of the company’s stock worth $249,158,000 after purchasing an additional 82,560 shares during the period. Price T Rowe Associates Inc. MD raised its stake in shares of Ionis Pharmaceuticals by 9.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,987,840 shares of the company’s stock worth $236,370,000 after buying an additional 258,155 shares in the last quarter. Finally, Tweedy Browne Co LLC raised its stake in shares of Ionis Pharmaceuticals by 0.3% during the 3rd quarter. Tweedy Browne Co LLC now owns 2,901,216 shares of the company’s stock worth $189,798,000 after buying an additional 9,268 shares in the last quarter. Hedge funds and other institutional investors own 93.86% of the company’s stock.

More Ionis Pharmaceuticals News

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Positive Sentiment: Barclays raised its price target to $106 and moved to an “overweight” rating, implying roughly ~43% upside from current levels — a clear catalyst for buying interest. Barclays PT raise (Benzinga)
• Positive Sentiment: 247WallSt summarized Barclays’ bullish thesis (calls for a ~45% move to $106), reinforcing the same positive narrative and helping momentum among growth/biotech investors. Why Barclays Thinks Ionis Is Headed for a 45% Surge
• Positive Sentiment: Needham raised its target to $105 and kept a “buy” rating, adding to the cluster of upward revisions that make the stock appealing to traders chasing analyst-led breakouts. Needham PT raise (Benzinga)
• Positive Sentiment: HC Wainwright boosted its target to $120 and reiterated a Buy, and its analyst also modeled a much improved FY‑2027 EPS (-$0.35 vs. much deeper consensus losses), signaling expectations for near‑term improvement in profitability assumptions. HC Wainwright research note (MarketBeat)
• Positive Sentiment: MSN reports Ionis repriced a drug ahead of a key FDA decision, which the company frames as positioning the therapy for a larger commercial market — a strategic move that could lift revenue assumptions if the FDA outcome is favorable. Ionis repriced drug ahead of FDA decision (MSN)
• Neutral Sentiment: A comparative head‑to‑head writeup vs. Innate Pharma provides market context but doesn’t add a direct catalyst; useful for longer‑term investors researching relative positioning. Head to Head Analysis (AmericanBankingNews)
• Negative Sentiment: Company insider Eugene Schneider sold 5,812 shares — a modest-sized sale that investors may watch for pattern changes but likely not material on its own. Insider sale report (AmericanBankingNews)

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.